Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 941
Filter
2.
Tokai J Exp Clin Med ; 49(1): 31-34, 2024 Apr 20.
Article in English | MEDLINE | ID: mdl-38509011

ABSTRACT

Low-grade endometrial stromal sarcoma (LG-ESS) is a rare uterine neoplasm. Computed tomography (CT) revealed the presence of multiple small bilateral pulmonary nodules in a 58-year-old woman 1 year after surgery for LG-ESS; the clinical diagnosis was pulmonary metastasis. Hormone therapy with progesterone was initiated, after which most of the solid nodules disappeared and some transformed into cystic lesions. Seven years after hormone therapy, the patient experienced repeated pneumothorax. The cause of the pneumothorax was perforation of a metastatic focus within the wall of a small subpleural cyst that was not evident on CT images.


Subject(s)
Endometrial Neoplasms , Pneumothorax , Sarcoma, Endometrial Stromal , Uterine Neoplasms , Female , Humans , Middle Aged , Endometrial Neoplasms/pathology , Sarcoma, Endometrial Stromal/surgery , Sarcoma, Endometrial Stromal/diagnosis , Sarcoma, Endometrial Stromal/pathology , Pneumothorax/diagnostic imaging , Pneumothorax/etiology , Hormones
3.
J Cancer Res Ther ; 20(1): 150-155, 2024 Jan 01.
Article in English | MEDLINE | ID: mdl-38554313

ABSTRACT

BACKGROUND: Endometrial stromal tumors (ESTs) are rare subset of mesenchymal uterine neoplasms. There are heterogeneous morphological, immunohistochemical, and genetic features. Approximately 50% of ESTs occur in perimenopausal women. In 2020, WHO sub-categorized ESTs into four groups: endometrial stromal nodule (ESN), low-grade endometrial stromal sarcoma (LGESS), high-grade endometrial stromal sarcoma (HGESS), and undifferentiated uterine sarcoma (UUS). OBJECTIVE: To review the morphological spectrum of endometrial stromal tumors. METHOD: This retrospective study reviewed the histomorphological features of 15 endometrial stromal tumors with respect to atypia, necrosis, mitosis, collagen bands, whorling around vessels, myometrial invasion, and inflammatory cells. Immunohistochemistry markers (CD10, SMA, and ER) along with special stains (Masson's trichrome, toluidine blue) were also studied. RESULTS: The age of the patients ranged from 32 to 60 years. Three patients were postmenopausal. The most common presenting symptom was vaginal bleeding. Five patients were operated with a clinical diagnosis of uterine fibroid. One patient presented with prolapse with no other complaint. All the 15 patients had total abdominal hysterectomy and salpingo-oophorectomy. One case showed necrosis, eight cases showed collagen bands, all the 15 cases showed whorling around vessels, one case showed vascular emboli, and seven cases showed inflammatory cells. In low-grade cases, one case showed focal atypia and one case showed focal coagulative necrosis indicating infarction. Thirteen cases were LGESS, and one case of ESN and HGESS. All cases were positive for ER and CD10. CONCLUSION: Endometrial stromal tumors demonstrate extensive permeation of the myometrium as irregular islands with frequent vascular invasion, whorling around vessels, collagen bands, and inflammatory cells. All these features should be observed thoroughly on microscopy by pathologists to clearly differentiate the low-grade and high-grade endometrial stromal tumors, and to understand the overlapping gray areas morphologically as it affects the prognosis of the patient.


Subject(s)
Endometrial Neoplasms , Endometrial Stromal Tumors , Sarcoma, Endometrial Stromal , Uterine Neoplasms , Humans , Female , Adult , Middle Aged , Endometrial Stromal Tumors/diagnosis , Endometrial Stromal Tumors/pathology , Sarcoma, Endometrial Stromal/diagnosis , Sarcoma, Endometrial Stromal/surgery , Endometrial Neoplasms/diagnosis , Endometrial Neoplasms/surgery , Endometrial Neoplasms/genetics , Retrospective Studies , Collagen , Necrosis
4.
Int J Surg ; 110(4): 1919-1928, 2024 Apr 01.
Article in English | MEDLINE | ID: mdl-38329091

ABSTRACT

OBJECTIVE: Little is known about the survival differences between uterine and extrauterine low-grade endometrial stromal sarcoma (LGESS). Survival outcomes, consisting of disease-free survivals and overall survivals (OS), were compared in these two entities. METHODS: From February 2012 to June 2019, all primary LGESS cases and LGESS cases with first recurrence in the study center were reviewed. The clinicopathological characteristics and survival outcomes of extrauterine and uterine LGESS patients were compared for both primary and recurrent diseases. RESULTS: During the study period, 143 patients with primary LGESS and 56 patients with recurrent LGESS were included and followed up to 1 June 2020, among whom 8 (5.6%) and 10 (17.8%) patients were identified as having extrauterine LGESS. Patients with primary and recurrent extrauterine LGESS had similar clinicopathological characteristics to those of patients with uterine LGESS. In primary or in recurrent LGESS cases, in univariate analysis, patients with uterine and extrauterine LGESS had similar disease-free intervals after the last treatment, and they also had similar OSs after the diagnosis. Ovarian preservation led to significantly increased recurrence for primary LGESS [hazard ratio (HR) 4.9, 95% CI: 2.3-10.1, P <0.001) and repeated recurrence for recurrent LGESS (HR 3.1, 95% CI: 1.3-7.3, P =0.009). Surgical treatment for recurrent LGESS decreased repeated recurrence after the first recurrence (HR 0.2, 95% CI: 0.1-0.7, P =0.006). No factors were found to be associated with the OS of primary or recurrent LGESS. CONCLUSION: The clinical characteristics and survival outcomes of extrauterine LGESS are similar to those of uterine LGESS. Surgery is the treatment of choice for recurrent LGESS. Ovarian preservation is detrimental to disease-free survival but not to OS in both uterine and extrauterine LGESS.


Subject(s)
Endometrial Neoplasms , Neoplasm Recurrence, Local , Sarcoma, Endometrial Stromal , Humans , Female , Sarcoma, Endometrial Stromal/pathology , Sarcoma, Endometrial Stromal/mortality , Sarcoma, Endometrial Stromal/surgery , Sarcoma, Endometrial Stromal/therapy , Sarcoma, Endometrial Stromal/diagnosis , Middle Aged , Endometrial Neoplasms/pathology , Endometrial Neoplasms/mortality , Endometrial Neoplasms/therapy , Endometrial Neoplasms/surgery , Endometrial Neoplasms/diagnosis , Adult , Prognosis , Retrospective Studies , Cohort Studies , Disease-Free Survival , Aged
7.
Sci Rep ; 14(1): 37, 2024 01 02.
Article in English | MEDLINE | ID: mdl-38167455

ABSTRACT

Diagnosing low-grade and high-grade endometrial stromal sarcoma (LG-ESS and HG-ESS) is a challenge. This study aimed to identify biomarkers. 22 ESS cases were analyzed using Illumina microarrays. Differentially expressed genes (DEGs) were identified via Limma. DEGs were analyzed with String and Cytoscape. Core genes were enriched with GO and KEGG, their pan-cancer implications and immune aspects were studied. 413 DEGs were found by exome sequencing, 2174 by GSE85383 microarray. 36 common genes were identified by Venn analysis, and 10 core genes including RBFOX1, PCDH7, FAT1 were selected. Core gene GO enrichment included cell adhesion, T cell proliferation, and KEGG focused on related pathways. Expression was evaluated across 34 cancers, identifying immune DEGs IGF1 and AVPR1A. Identifying the DEGs not only helps improve our understanding of LG-ESS, HG-ESS but also promises to be potential biomarkers for differential diagnosis between LG-ESS and HG-ESS and new therapeutic targets.


Subject(s)
Endometrial Neoplasms , Sarcoma, Endometrial Stromal , Female , Humans , Sarcoma, Endometrial Stromal/diagnosis , Sarcoma, Endometrial Stromal/genetics , Biomarkers, Tumor/metabolism , Gene Expression Profiling , Endometrial Neoplasms/diagnosis , Endometrial Neoplasms/genetics , Computational Biology
8.
Bull Cancer ; 111(1): 97-116, 2024 Jan.
Article in French | MEDLINE | ID: mdl-37806863

ABSTRACT

The landscape of uterine sarcomas is becoming more complex with the description of new entities associated with recurrent driver molecular alterations. Uterine sarcomas, in analogy with soft tissue sarcomas, are distinguished into complex genomic and simple genomic sarcomas. Leiomyosarcomas and undifferentiated uterine sarcomas belong to complex genomic sarcomas group. Low-grade and high-grade endometrial stromal sarcomas, other rare tumors associated with fusion transcripts (such as NTRK, PDGFB, ALK, RET ROS1) and SMARCA4-deficient uterine sarcoma are considered simple genomic sarcomas. The most common uterine sarcoma are first leiomyosarcoma and secondly endometrial stromal sarcomas. Three different histological subtypes of leiomyosarcoma (fusiform, myxoid, epithelioid) are identified, myxoid and epithelioid leiomyosarcoma being more aggressive than fusiform leiomyosarcoma. The distinction between low-grade and high-grade endometrial stromal sarcoma is primarily morphological and immunohistochemical and the detection of fusion transcripts can help the diagnosis. Uterine PEComa is a rare tumor, which is distinguished into borderline and malignant, according to a risk assessment algorithm. Embryonal rhabdomyosarcoma of the uterine cervix is more common in children but can also occur in adult women. Embryonal rhabdomyosarcoma of the uterine cervix is almost always DICER1 mutated, unlike that of the vagina which is wild-type DICER1, and adenosarcoma which can be DICER1 mutated but with less frequency. Among the emerging entities, sarcomas associated with fusion transcripts involving the NTRK, ALK, PDGFB genes benefit from targeted therapy. The integration of molecular data with histology and clinical data allows better identification of uterine sarcomas in order to better treat them.


Subject(s)
DEAD-box RNA Helicases , Endometrial Neoplasms , Genital Neoplasms, Female , Leiomyosarcoma , Rhabdomyosarcoma, Embryonal , Ribonuclease III , Sarcoma, Endometrial Stromal , Soft Tissue Neoplasms , Uterine Cervical Neoplasms , Uterine Neoplasms , Adult , Child , Female , Humans , Leiomyosarcoma/diagnosis , Leiomyosarcoma/genetics , Leiomyosarcoma/therapy , Rhabdomyosarcoma, Embryonal/diagnosis , Rhabdomyosarcoma, Embryonal/genetics , Rhabdomyosarcoma, Embryonal/therapy , Sarcoma, Endometrial Stromal/diagnosis , Sarcoma, Endometrial Stromal/genetics , Sarcoma, Endometrial Stromal/therapy , Protein-Tyrosine Kinases , Proto-Oncogene Proteins , Uterine Neoplasms/diagnosis , Uterine Neoplasms/genetics , Uterine Neoplasms/therapy , Receptor Protein-Tyrosine Kinases , DNA Helicases , Nuclear Proteins , Transcription Factors
9.
Am J Surg Pathol ; 48(1): 36-45, 2024 Jan 01.
Article in English | MEDLINE | ID: mdl-37867306

ABSTRACT

Low-grade endometrial stromal sarcoma (LGESS) represents a morphologically and genetically heterogenous mesenchymal neoplasm. Previous work has shown that approximately half of LGESS are characterized by JAZF1::SUZ12 gene fusions, while a smaller proportion involves rearrangement of other genes. However, a subset of cases has no known genetic abnormalities. To better characterize the genomic landscape of LGESS, we interrogated a cohort with targeted RNA sequencing (RNA-Seq). Cases previously diagnosed as low-grade endometrial stromal neoplasia (n=51) were identified and re-reviewed for morphology and subjected to RNA-Seq, of which 47 were successfully sequenced. The median patient age was 49 years (range: 19 to 85). The most commonly detected fusions were JAZF1::SUZ12 (n=26, 55%) and BRD8::PHF1 (n=3, 6%). In addition to the usual/typical LGESS morphology, some JAZF1::SUZ12 fusion tumors showed other morphologies, including fibrous, smooth muscle, sex-cord differentiation, and myxoid change. Novel translocations were identified in 2 cases: MEAF6::PTGR2 and HCFC1::PHF1 . Ten tumors (21%) had no identifiable fusion, despite a similar morphology and immunophenotype to fusion-positive cases. This suggests that a subset of cases may be attributable to fusion products among genes that are not covered by the assay, or perhaps altogether different molecular mechanisms. In all, these findings confirm that RNA-Seq is a potentially useful ancillary test in the diagnosis of endometrial stromal neoplasms and highlight their diverse morphology.


Subject(s)
Endometrial Neoplasms , Endometrial Stromal Tumors , Sarcoma, Endometrial Stromal , Female , Humans , Young Adult , Adult , Middle Aged , Aged , Aged, 80 and over , Sarcoma, Endometrial Stromal/pathology , Endometrial Neoplasms/pathology , Endometrial Stromal Tumors/genetics , Transcription Factors/genetics , Genomics , Sequence Analysis, RNA
10.
J Comp Pathol ; 208: 11-14, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38011771

ABSTRACT

An 11-year-old female Persian cat underwent ovariohysterectomy due to dilation of the uterine cavity with irregular thickening of the wall. Macroscopically, the middle and distal regions of the left uterine horn were swollen and the uterine wall was irregularly thickened due to the development of multiple coalescent, variably sized nodules. Microscopically, the nodules had originated in the endometrium and were composed of round to polygonal neoplastic cells arranged in dense sheets or ill-defined fascicles. The neoplastic cells had locally invaded the myometrium and reached the subserosa, with lymphovascular invasion. Immunohistochemically, the neoplastic cell population was partially positive for CD10, an established marker of endometrial stromal sarcoma (ESS) in humans, with focal and diffuse nuclear immunopositivity for oestrogen and progesterone receptors and immunonegativity for desmin and α-smooth muscle actin. Based on these findings, the uterine tumour was diagnosed as ESS and was considered to correspond morphologically to high-grade ESS in humans.


Subject(s)
Cat Diseases , Endometrial Neoplasms , Sarcoma, Endometrial Stromal , Uterine Neoplasms , Humans , Female , Cats , Animals , Sarcoma, Endometrial Stromal/veterinary , Sarcoma, Endometrial Stromal/diagnosis , Sarcoma, Endometrial Stromal/pathology , Endometrial Neoplasms/veterinary , Endometrial Neoplasms/diagnosis , Endometrial Neoplasms/pathology , Uterine Neoplasms/veterinary , Uterine Neoplasms/pathology , Receptors, Progesterone
11.
Histopathology ; 84(3): 451-462, 2024 Feb.
Article in English | MEDLINE | ID: mdl-37988282

ABSTRACT

AIMS: NTRK-rearranged sarcomas of the female genital tract mainly occur in the uterus (more commonly cervix than corpus) and are characterized by a "fibrosarcoma-like" morphology and NTRK gene rearrangements. These neoplasms may exhibit histological overlap with other entities and can present diagnostic difficulties without molecular confirmation. Pan-TRK immunohistochemistry was developed to identify tumours harbouring NTRK rearrangements. The aim of this study was to characterize pan-TRK immunohistochemical expression in a large cohort of gynaecological mesenchymal neoplasms and investigate the utility of pan-TRK immunohistochemistry to distinguish NTRK-rearranged sarcoma from its mimics. METHODS AND RESULTS: A total of 473 gynaecological mesenchymal tumours (461 without known NTRK fusions and 12 NTRK-rearranged sarcomas) were selected. Pan-TRK immunohistochemistry (EPR17341, Abcam) was performed on whole tissue sections and tissue microarrays. Molecular interrogation of pan-TRK positive tumours was performed by RNA sequencing or fluorescence in situ hybridization (FISH). Of the 12 NTRK-rearranged sarcomas, 11 (92%) exhibited diffuse (≥70%) cytoplasmic pan-TRK staining with moderate/marked intensity, while the other was negative. Eleven (2.4%) additional tumours also exhibited pan-TRK immunohistochemical expression: three low-grade endometrial stromal sarcomas, seven high-grade endometrial stromal sarcomas, and an undifferentiated uterine sarcoma. Molecular confirmation of the absence of NTRK rearrangements was possible in nine of these tumours. Of these nine neoplasms, seven exhibited focal/multifocal (<70%) pan-TRK cytoplasmic staining with weak/moderate intensity. CONCLUSION: Even though pan-TRK immunohistochemical expression is not entirely sensitive or specific for NTRK-rearranged sarcomas, these neoplasms tend to exhibit diffuse staining of moderate/strong intensity, unlike its mimics. Pan-TRK should be performed in monomorphic uterine (corpus and cervix) spindle cell neoplasms that are negative for smooth muscle markers and hormone receptors and positive for CD34 and/ or S100. Ultimately, the diagnosis requires molecular confirmation.


Subject(s)
Endometrial Neoplasms , Neoplasms, Connective and Soft Tissue , Sarcoma, Endometrial Stromal , Sarcoma , Soft Tissue Neoplasms , Female , Humans , Biomarkers, Tumor/genetics , Immunohistochemistry , In Situ Hybridization, Fluorescence , Oncogene Proteins, Fusion/genetics , Sarcoma/diagnosis , Sarcoma/genetics , Sarcoma/pathology , Receptor, trkA
12.
Int J Gynecol Pathol ; 43(1): 33-40, 2024 Jan 01.
Article in English | MEDLINE | ID: mdl-36811828

ABSTRACT

Endometrial stromal tumors represent the second most common category of uterine mesenchymal tumors. Several different histologic variants and underlying genetic alterations have been recognized, one such being a group associated with BCORL1 rearrangements. They are usually high-grade endometrial stromal sarcomas, often associated with prominent myxoid background and aggressive behavior. Here, we report an unusual endometrial stromal neoplasm with JAZF1-BCORL1 rearrangement and briefly review the literature. The neoplasm formed a well-circumscribed uterine mass in a 50-yr-old woman and had an unusual morphologic appearance that did not warrant a high-grade categorization. It was characterized by a predominant population of epithelioid cells with clear to focally eosinophilic cytoplasm growing in interanastomosing cords and trabeculae set in a hyalinized stroma as well as nested and fascicular growths imparting focal resemblance to a uterine tumor resembling ovarian sex-cord tumor, PEComa, and a smooth muscle neoplasm. A minor storiform growth of spindle cells reminiscent of the fibroblastic variant of low-grade endometrial stromal sarcoma was also noted but conventional areas of low-grade endometrial stromal neoplasm were not identified. This case expands the spectrum of morphologic features seen in endometrial stromal tumors, especially when associated with a BCORL1 fusion and highlights the utility of immunohistochemical and molecular techniques in the diagnosis of these tumors, not all of which are high grade.


Subject(s)
Endometrial Neoplasms , Endometrial Stromal Tumors , Sarcoma, Endometrial Stromal , Uterine Neoplasms , Female , Humans , Endometrial Stromal Tumors/diagnosis , Endometrial Stromal Tumors/genetics , Endometrial Neoplasms/diagnosis , Endometrial Neoplasms/genetics , Endometrial Neoplasms/chemistry , Sarcoma, Endometrial Stromal/diagnosis , Sarcoma, Endometrial Stromal/genetics , Uterine Neoplasms/pathology , Uterus/pathology , DNA-Binding Proteins/genetics , Co-Repressor Proteins/genetics , Repressor Proteins/genetics
13.
Int J Gynecol Pathol ; 43(1): 47-55, 2024 Jan 01.
Article in English | MEDLINE | ID: mdl-37043646

ABSTRACT

MEIS1::NCOA1/2 fusion sarcomas are a recently described novel entity arising in a variety of locations with a predilection for the genitourinary tract and gynecologic organs. Despite multiple locoregional recurrences, these tumors are thought to behave in a low-grade malignant manner. Here we report a uterine MEIS1::NCOA2 fusion sarcoma with lung metastasis. The patient was a 47-yr-old woman with a history of abnormal uterine bleeding who was found to have a myometrial mass confirmed by pathology to be uterine sarcoma. The tumor was predominantly composed of monotonous spindle cells with scant cytoplasm, crowded nuclei, and brisk mitotic activity, growing in a fascicular and streaming pattern. The morphologic and immunophenotypic features were nonspecific and a diagnosis of high-grade uterine sarcoma with a differential of leiomyosarcoma versus high-grade endometrial stromal sarcoma was rendered. At the 27-mo follow-up, the patient was found to have a lung metastasis consisting of a monotonous round cell sarcoma. A retrospective RNA-based and DNA-based next-generation sequencing of the primary uterine sarcoma revealed a MEIS1::NCOA2 gene fusion, a c.94G>C/p.D32H mutation in exon 3 of CTNNB1 gene, HMGA2 , and CDK4 gene amplification, and an intermediate/marginal level of MDM2 gene amplification. Polymerase chain reaction-based molecular analysis further demonstrated that the MEIS1::NCOA2 gene fusion and CTNNB1 somatic mutation were also present in the lung metastasis. This case represents the first case of such gynecologic sarcoma with distant (lung) metastasis, and the second metastatic case among all reported MEIS1::NCOA1/2 fusion sarcomas, highlighting the malignant metastatic potential of this emerging entity. Our case also indicates that HMGA2/CDK4/MDM2 region amplification and CTNNB1 somatic mutation might be recurrent genetic events in this rare sarcoma subtype.


Subject(s)
Endometrial Neoplasms , Lung Neoplasms , Sarcoma, Endometrial Stromal , Sarcoma , Uterine Neoplasms , Humans , Female , Retrospective Studies , Neoplasm Recurrence, Local , Sarcoma/pathology , Uterine Neoplasms/genetics , Uterine Neoplasms/pathology , Sarcoma, Endometrial Stromal/pathology , Endometrial Neoplasms/pathology , Lung Neoplasms/genetics , Biomarkers, Tumor/analysis , Nuclear Receptor Coactivator 2/genetics
14.
Indian J Pathol Microbiol ; 66(4): 829-833, 2023.
Article in English | MEDLINE | ID: mdl-38084541

ABSTRACT

Several defining molecular alterations have recently been identified underlying high-grade endometrial stromal sarcomas, such as YWHAE: NUTM2A/B fusions, ZC3H7B: BCOR fusions, and BCOR internal tandem duplication (ITD). BCOR is a useful immunohistochemical marker for identifying these tumors. A 37-year-old lady was presented with a 10-cm-sized tumor in the pouch of Douglas, involving the vaginal vault, bilateral adnexa, and peritoneum. A 53-year-old lady with a prior hysterectomy was presented with a 12-cm-sized tumor in the vault with abdominal deposits. Histopathological examination of both tumors revealed atypical cells comprising oval to spindle-shaped nuclei, a variable amount of myxoid stroma, and mitotic figures exceeding 10/10 high power fields. Immunohistochemically, the former tumor was diffusely positive for CD10, and the second tumor displayed patchy staining. Both tumors were positive for BCOR. Estrogen receptor (ER) showed variable staining in both tumors. By fluorescence in-situ hybridization (FISH), both tumors lacked YWHAE gene rearrangement. Both tumors had an aggressive clinical course, including extensive involvement This constitutes the first report of BCOR-positive high-grade sarcomas involving the female genital tract from our subcontinent. BCOR is a useful immunostain for identifying these relatively aggressive tumors. The differential diagnoses and the prognosis of these ultra-rare tumors are discussed herewith.


Subject(s)
Endometrial Neoplasms , Sarcoma, Endometrial Stromal , Sarcoma , Humans , Female , Adult , Middle Aged , Sarcoma, Endometrial Stromal/diagnosis , Sarcoma, Endometrial Stromal/genetics , Repressor Proteins/genetics , Proto-Oncogene Proteins/genetics , Sarcoma/pathology , Biomarkers, Tumor/genetics , Endometrial Neoplasms/diagnosis , Endometrial Neoplasms/genetics , Endometrial Neoplasms/chemistry
16.
Int J Gynecol Pathol ; 42(6): 597-601, 2023 Nov 01.
Article in English | MEDLINE | ID: mdl-37562066

ABSTRACT

High-grade endometrial stromal sarcomas with ZC3H7B-BCOR fusion are rare. They are predominantly located in the endomyometrium, with morphologic features characterized as haphazardly arranged fascicles of spindle cells with mild to moderate atypia, abundant myxoid matrix, high mitotic index, and tongue-like/pushing patterns of myometrial invasion. Furthermore, conventional or variant low-grade endometrial stromal sarcomas are often not present. Clinically, they present at a higher stage and are associated with worse prognosis compared with low-grade endometrial stromal sarcoma. Given the limited number of reported cases, we describe the case of a ZC3H7B-BCOR fusion high-grade endometrial stromal sarcoma initially diagnosed on the hysterectomy specimen as low-grade endometrial stromal sarcoma based on an endometrial stromal tumor showing tongue-like myometrial and lymphovascular invasion, minimal cytologic atypia, low-mitotic activity (0-1/10 high-power field), round/spindle cell component and immunohistochemical stain results (positive for CD10, estrogen receptor, progesterone receptor, and focally positive for cyclin D1). At the time of pathologic diagnosis, she was Stage Ia and managed conservatively. Subsequent molecular analysis revealed a ZC3H7B (exon 10)- BCOR (BCL-6 corepressor) (exon 7) gene fusion. On follow-up, she showed no evidence of disease at 37 months from the time of diagnosis. This case report expands the morphologic spectrum of ZC3H7B-BCOR fusion high-grade ESS, which includes an intramural location, morphologic and immunophenotypic features similar to LG-ESS, as well as the presence of round and spindle cell components. This case also underscores the value of molecular analysis in the proper classification of ESS.


Subject(s)
Endometrial Neoplasms , Endometrial Stromal Tumors , Sarcoma, Endometrial Stromal , Female , Humans , Sarcoma, Endometrial Stromal/diagnosis , Sarcoma, Endometrial Stromal/genetics , Sarcoma, Endometrial Stromal/surgery , Endometrial Stromal Tumors/diagnosis , Repressor Proteins/metabolism , Endometrial Neoplasms/genetics , Proto-Oncogene Proteins/genetics , Transcription Factors , RNA-Binding Proteins
17.
Am J Surg Pathol ; 47(11): 1285-1290, 2023 11 01.
Article in English | MEDLINE | ID: mdl-37584555

ABSTRACT

Endometrial/endometrioid stromal tumors are rare and morphologically heterogenous, and their diagnosis may be challenging. We identified 3 endometrial/endometrioid stromal tumors with identical and previously undescribed histologic features and herein report their morphologic, immunohistochemical, and molecular profiles. Patients were 53, 62, and 79 years. Tumors were well-circumscribed, tan-yellow solid masses measuring 10.0, 11.0, and 18.7 cm, and were intramyometrial (n=2) or in the broad ligament (n=1). All showed small, tight whorls of epithelioid to slightly spindled tumor cells with minimal cytoplasm and negligible mitoses, multifocally associated with hyalinization and myxoid change set in a loose fibroblastic background with small, delicate vessels. This morphology was seen throughout in 1 tumor and in ∼20% and 70% of the 2 others with the remaining areas showing sex cord-like differentiation. Tumor cells expressed CD10 (3/3, 1 focal), calretinin (3/3 diffuse), WT1 (3/3 diffuse), estrogen receptor (1/1, diffuse). RNA-sequencing was successful in 1 tumor and revealed a GREB1-CTNNB1 in-frame fusion. All 3 tumors harbored a CTNNB1 translocation by fluorescence in situ hybridization correlating with nuclear ß-catenin expression. Whole-genome DNA methylation analysis classified all 3 tumors within the low-grade endometrial stromal sarcoma reference class with flat copy number profiles. One patient (79-y-old) died of unrelated causes 2 months after surgery and the other 2 were alive without disease after 13 and 75 months. We have described a rare subset of endometrial/endometrioid stromal tumors with extensive whorling and a CTNNB1 translocation, expanding the morphologic and molecular spectrum of these neoplasms.


Subject(s)
Endometrial Neoplasms , Endometrial Stromal Tumors , Sarcoma, Endometrial Stromal , Female , Humans , beta Catenin/genetics , In Situ Hybridization, Fluorescence , Endometrial Stromal Tumors/pathology , Mitosis , Endometrial Neoplasms/genetics , Endometrial Neoplasms/surgery , Endometrial Neoplasms/metabolism , Biomarkers, Tumor/genetics , Biomarkers, Tumor/analysis , Sarcoma, Endometrial Stromal/genetics , Sarcoma, Endometrial Stromal/surgery , Sarcoma, Endometrial Stromal/pathology
19.
BMC Womens Health ; 23(1): 394, 2023 07 26.
Article in English | MEDLINE | ID: mdl-37496042

ABSTRACT

BACKGROUND: Uterine sarcomas are uncommon mesenchymal tumors of the uterus. The clinical problem is that the features of uterine sarcomas can sometimes mimic uterine fibroids. This study aims to investigate the clinical characteristics of patients with uterine sarcomas who were preoperative presenting mainly with uterine masses. METHODS: A retrospective analysis of patients who underwent gynecological surgery for uterine sarcomas at the Obstetrics & Gynecology Hospital of Fudan University, between January 2016 and December 2021. RESULTS: Over the 5-year period, 277 patients were final diagnosed of uterine sarcomas. A total of 162 patients were preoperatively diagnosed as uterine fibroids for surgical treatment, the majority of whom were diagnosed of uterine leiomyosarcoma (uLMS) (49/162) and low-grade endometrial stromal sarcoma (LG-ESS) (100/162). Ninety people underwent total hysterectomy and bilateral salpingo-oophorectomy (TH + BSO), while 72 underwent myomectomy followed by supplemental TH + BSO. The group with direct hysterectomy had a higher average age than the group with prior myomectomy (47.20 ± 8.94 vs. 40.86 ± 5.88, p < 0.001). Among patients preoperatively diagnosed as uterine fibroids, patients with uLMS had a higher proportion of previous myomectomy (26.53% vs. 5.00%, p < 0.001), a larger uterine mass diameter on ultrasound (8.38 ± 3.39 cm vs. 6.41 ± 1.92 cm, p < 0.001), and richer hypervascularity (34.69% vs. 18%, p = 0.024) compared with LG-ESS. CONCLUSIONS: Analysis of our data showed that a large proportion of uterine sarcomas, especially uLMS and LG-ESS, present mainly with uterine masses. Ultrasound features including a large uterine mass diameter and rich hypervascularity, and with a history of myomectomy may alert clinicians in suspicion of uLMS when compared with LG-ESS.


Subject(s)
Endometrial Neoplasms , Leiomyoma , Leiomyosarcoma , Pelvic Neoplasms , Sarcoma, Endometrial Stromal , Sarcoma , Uterine Neoplasms , Female , Humans , Retrospective Studies , Sarcoma, Endometrial Stromal/diagnosis , Sarcoma, Endometrial Stromal/surgery , Sarcoma, Endometrial Stromal/pathology , Uterine Neoplasms/diagnostic imaging , Uterine Neoplasms/surgery , Sarcoma/diagnostic imaging , Sarcoma/surgery , Leiomyosarcoma/diagnostic imaging , Leiomyosarcoma/surgery , Leiomyoma/surgery , Hysterectomy , Endometrial Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...